Alessio Amatu

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino et al. · Nature Medicine · 2015 · 1.1K citations · Full text

Medicine, Pathology, Colorectal Cancer +6

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 984 citations · Full text

Oncology, Medicine, Pathology +5

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 795 citations · Full text

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Alberto Bardelli, Simona Corso, Andrea Bertotti et al. · Cancer Discovery · 2013 · 654 citations · Full text

Engineering, Pathology, Cancer Biology +17

Adaptive mutability of colorectal cancers in response to targeted therapies

Mariangela Russo, Giovanni Crisafulli, Alberto Sogari et al. · Science · 2019 · 425 citations · Full text

Pathology, Cancer Biology, Tumor Biology +16